Compare PepsiCo, Inc. (PEP) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs Twist Bioscience Corp — how do they compare? PepsiCo, Inc. trades at $127.5 (market cap $174.89B), while Twist Bioscience Corp trades at $154.45 (market cap $10.08B). The key difference: PepsiCo, Inc. is far larger — about 17.4× Twist Bioscience Corp's market cap, and PepsiCo, Inc. pays a 4.61% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold PepsiCo, Inc. for 107 Days and Twist Bioscience Corp for 27 Days on average.
| PEP | TWST | |
|---|---|---|
Market Cap | $174.89B | $10.08B |
Volume | 23,968,864 | 4,229,037 |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $205.00 |
52-Week Low | $123.64 | $25.45 |
Typical Hold Time | 107 Days | 27 Days |
Enterprise Value | $215.61B | $10.01B |
Dividend Yield | 4.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $123.64, down 1.65% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS of $2.34 surpassing the $2.29 expectation. Revenue reached $93.93B in 2025, though net income margin dipped to 8.77%. Recent news highlights price cuts on snacks like Doritos to address consumer pushback on high prices.
The outlook is mixed: strong profitability metrics like a 51.59% ROE and a consensus analyst price target of $146.77 suggest upside potential, but competitive pressures and recent net margin compression pose risks. Institutional activity shows mixed signals with some firms increasing stakes while others reduce holdings.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
